The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
In patients receiving immune checkpoint inhibition to treat their metastatic urothelial carcinoma, immune-related adverse effects may serve as a prognostic marker for progression-free and overall survival.
A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy.
Patients with prostate cancer fared better following treatment with magnetic resonance-guided focused ultrasound focal therapy than with radical prostatectomy or radiation therapy, shows study presented at 2021 AUA Annual Meeting.
Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.